------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Two Leading Biotech Publications Report on Advaxis' Potential
Treatment for Cervical Cancer

PRINCETON, N.J. Dec 12, 2005 - Two leading biotech publications
reported that Advaxis, Inc. (ADXS.OB) successfully demonstrated in
testing of mice at the University of Pennslyvania that a live
listeria vaccine can eradicate existing, rapidly-growing breast
tissue tumors.

Genetic Engineering News, in its December 8th issue, reported that
Dr. Yvonne Paterson, professor of microbiology at the University of
Pennsylvania, and chair person of Advaxis' Scientific Advisory
Board, presented a study in a recent issue of the Journal of
Immunology that ten years of scientific research produced evidence
of the cancer-fighting properties of a live modified listeria cancer
vaccine she created.

Dr. Paterson's research indicates that listeria activates the body's
cytotoxic T cells to help the immune system take a stronger stance
in the presence of cancer cells, Genetic Engineering News reported.

"If Lovaxin C is successful in clinical trials it has the potential
for <a href="http://www.imhcaz.com/" >treating cervical cancer</a>
in early and late stage disease, including those women who have
positive pap smears and currently require surgery," explained John
Rothman, Advaxis'vice president of clinical development.

DrugResearcher.com, reported in its December 6th issue that Advaxis'
Lovaxin C, a proprietary listeria vaccine, "could soon be on the
horizon after researchers took a giant step in development of
effective cancer-fighting vaccines that appear to be able to stop
and reverse cancer growth."

"The newly developed vaccine therapies for cervical cancer are
directed at those women who have not been exposed to HPV, the viral
cause of cervical cancer," DrugResearcher.com reported. "Lovaxin C,
which will be entering a Phase I/II clinical trial, is intended to
cure women who already have cervical cancer as a result of HPV
exposure."

The two articles can be found at:

www.drugresearcher.com/news/ng.asp?n=64376-advaxis-listeria -cancer
and www.genengnews.com/stickyends/article.aspx?sid=149. (Due to the
length of this URL, it may be necessary to copy and paste this
hyperlink into your Internet browser's URL address field.)

About Advaxis

Based in Princeton, New Jersey. Advaxis is developing proprietary
Listeria cancer vaccines based on technology developed by Dr. Yvonne
Paterson, professor of microbiology at the University of
Pennsylvania, and chair person of Advaxis' Scientific Advisory
Board.. Advaxis' is developing therapeutic cancer vaccines that
enhance the immune system's cancer-fighting abilities through its
proprietary Listeria monocytogenes based system, which utilizes two
immunological mechanisms (Innate and Classical Immunity) to develop
safer and more effective Listeria based cancer vaccines. Advaxis is
the exclusive licensee of a patented broadly enabling Listeria
platform technology that can elicit effective anti-tumor responses.
Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets
cervical and head and neck cancers. Further Listeria vaccines in
development target breast, ovarian and lung cancers. Advaxis is
entering a Phase I/II clinical trial in late 2005. The Listeria
platform will also have applications in the fields of infectious
disease and autoimmune disorders.

Forward-Looking Statements

Certain statements contained in this press release are forward-
looking statements that involve risks and uncertainties. The
statements contained herein that are not purely historical are
forward looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements deal
with the Company's current plans, intentions, beliefs and
expectations and statements of future economic performance. Forward-
looking statements involve known and unknown risks and uncertainties
that may cause the Company's actual results in future periods to
differ materially from what is currently anticipated. Factors that
could cause or contribute to such differences include those
discussed from time to time in reports filed by the Company with the
Securities and Exchange Commission. The Company cannot guarantee its
future results, levels of activity, performance or achievements.

http://www.imhcaz.com/
http://www.azhttp.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech